Eisbach Bio GmbH receives CRPIT Grant to promote new cancer drugs
LMU spin-off Eisbach Bio GmbH has received a Texas Therapeutics Company Award from the Cancer Prevention and Research Institute of Texas (CPRIT). This grant will support the clinical development of EIS-12656, which targets challenging cancers with homologous recombination defects (HRD). Eisbach Bio GmbH had previously secured $4.5 million in funding in June 2024. Juni 2024 4,5 Mio $ Fördermittel gesichert.
